Cargando…
Concepts and clinical use of ultra-long basal insulin
Diabetes mellitus (DM) is a public health issue, affecting around 382 million people worldwide. In order to achieve glycemic goals, insulin therapy is the frontline therapy for type 1 DM patients; for patients with type 2 DM, use of insulin therapy is an option as initial or add-on therapy for those...
Autores principales: | Eliaschewitz, Freddy Goldberg, Barreto, Tânia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4702396/ https://www.ncbi.nlm.nih.gov/pubmed/26740822 http://dx.doi.org/10.1186/s13098-015-0117-1 |
Ejemplares similares
-
Degludec: the new ultra-long insulin analogue
por: Tambascia, Marcos Antonio, et al.
Publicado: (2015) -
Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
por: Jonassen, Ib, et al.
Publicado: (2012) -
Influence of gastric emptying on the control of postprandial glycemia: physiology and therapeutic implications
por: Tambascia, Marcos Antonio, et al.
Publicado: (2014) -
Advances in GLP-1 treatment: focus on oral semaglutide
por: Eliaschewitz, Freddy G., et al.
Publicado: (2021) -
Insulin Degludec, a Novel Ultra-Long-Acting Basal Insulin versus Insulin Glargine for the Management of Type 2 Diabetes: A Systematic Review and Meta-Analysis
por: Zhou, Wenchuan, et al.
Publicado: (2019)